Clinical trial participant information leaflets overstate the harms/risks of participation and understate the benefits
PLOS One · 05.05.2026 · 21 (5) · e0346984
DOI: 10.1371/journal.pone.0346984 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 05.05.2026. Verfasst von Rafaela Carapeto und 2 weiteren Autor:innen. Beteiligte Einrichtung: Trials Research and Methodologies Unit, HRB Clinical Research Facility, University College Cork, Cork, Ireland. Hauptthemen laut MEDLINE: Pamphlets, Informed Consent, Randomized Controlled Trials as Topic, Patient Participation. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Participant Information Leaflets (PILs) are essential for informed consent in randomised controlled trials (RCTs), detailing the trial’s purpose, methods, and potential benefits and harms/risks to aid participant decision-making. The purpose of our study was to establish the balance of benefits and harms/risks communicated to trial participants in PILs. Study Design and Setting A retrospective study of 228 PILs from trials in the UK and Ireland. Benefits and harms/risks were defined and quantified through a systematic extraction and coding process. The analysis included the calculation of mean, median, and ranges for word counts of positive and negative reinforcement statements, and their proportional representation in the overall content of the PILs.
Results
The study included PILs from 26 Clinical Trial Units and Clinical Research Facilities, covering 228 unique studies in the UK and Ireland. The word count for positive reinforcement statements (median: 56 words, 2.3% of total PIL word count) was significantly lower than for negative reinforcement statements (median: 149 words, 5.7% of total PIL word count). Approximately 72% of PILs contained a higher percentage of words dedicated to negative rather than positive reinforcement, indicating an imbalance in presenting harms/risks over benefits.
Conclusions
The findings suggest that information in participant information leaflets places greater emphasis on potential harms and risks than on potential benefits of trial participation. While regulatory requirements necessitate clear communication of possible harms, the relatively limited emphasis on potential benefits may influence how participants interpret trial information. These findings highlight the importance of ensuring that participant-facing materials present both potential harms and benefits in a balanced and accessible way to support informed decision-making. Greater guidance for trial teams on how to present this information may help improve the clarity and balance of participant information leaflets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Trials Research and Methodologies Unit, HRB Clinical Research Facility, University College Cork, Cork, Ireland.
- Health Service Executive, Cork, Ireland.
- School of Public Health, University College Cork, Cork, Ireland.
ORCID-Profile: Frances Shiely
Zitieren
APA
Carapeto, R., Willis, A., & Shiely, F. (2026). Clinical trial participant information leaflets overstate the harms/risks of participation and understate the benefits. PLOS One, 21(5), e0346984. https://doi.org/10.1371/journal.pone.0346984
Vancouver
Carapeto R, Willis A, Shiely F. Clinical trial participant information leaflets overstate the harms/risks of participation and understate the benefits. PLOS One. 2026;21(5):e0346984. doi:10.1371/journal.pone.0346984
BibTeX
@article{Carapeto2026,
author = {Carapeto, Rafaela and Willis, Andrew and Shiely, Frances},
title = {Clinical trial participant information leaflets overstate the harms/risks of participation and understate the benefits},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {5},
pages = {e0346984},
doi = {10.1371/journal.pone.0346984}
}
EUVIMED